Genetic differences in cytochrome P450 enzymes and antidepressant treatment response

Biomarkers predicting treatment outcome in depression: what is clinically significant?

(2012) Rudolf Uher et al.   PHARMACOGENOMICS

Genetic Predictors of Response to Serotonergic and Noradrenergic Antidepressants in Major Depressive Disorder: A Genome-Wide Analysis of Individual-Level Data and a Meta-Analysis

(2012) Katherine E. Tansey et al.   PLOS MEDICINE

Using a pharmacogenomic algorithm to guide the treatment of depression

(2012) D K Hall-Flavin et al.   Translational Psychiatry

CYP2C19 genotype predicts steady state escitalopram concentration in GENDEP

(2011) Patricia Huezo-Diaz et al.   JOURNAL OF PSYCHOPHARMACOLOGY

Genome-Wide Pharmacogenetics of Antidepressant Response in the GENDEP Project

(2010) Rudolf Uher et al.   AMERICAN JOURNAL OF PSYCHIATRY

CYP2C19 variation and citalopram response

(2010) David A. Mrazek et al.   Pharmacogenetics and Genomics

Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response

(2010) Ming-Hsien Tsai et al.   PHARMACOGENOMICS

Genetic predictors of response to antidepressants in the GENDEP project

(2009) Rudolf Uher et al.   PHARMACOGENOMICS JOURNAL

Serum Concentrations of Antidepressant Drugs in a Naturalistic Setting: Compilation Based on a Large Therapeutic Drug Monitoring Database

(2009) Margareta Reis et al.   THERAPEUTIC DRUG MONITORING

The AmpliChip CYP450 test: cytochrome P450 2D6 genotype assessment and phenotype prediction

(2008) M C Rebsamen et al.   PHARMACOGENOMICS JOURNAL

Pharmacokinetic Genes Do Not Influence Response or Tolerance to Citalopram in the STAR*D Sample

(2008) Eric J. Peters et al.   PLoS One